Zevra Therapeutics Inc (ZVRA)
9.585
+0.46
(+4.98%)
USD |
NASDAQ |
Nov 22, 16:00
9.64
+0.06
(+0.57%)
After-Hours: 20:00
Zevra Therapeutics Cash from Operations (Quarterly): -18.14M for Sept. 30, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -18.14M |
| June 30, 2024 | -19.11M |
| March 31, 2024 | -16.16M |
| December 31, 2023 | -16.16M |
| September 30, 2023 | -4.628M |
| June 30, 2023 | -8.704M |
| March 31, 2023 | -4.045M |
| December 31, 2022 | -4.462M |
| September 30, 2022 | -6.598M |
| June 30, 2022 | -4.104M |
| March 31, 2022 | -3.553M |
| December 31, 2021 | -0.848M |
| September 30, 2021 | -2.73M |
| June 30, 2021 | 16.60M |
| March 31, 2021 | -2.586M |
| December 31, 2020 | -1.059M |
| September 30, 2020 | -1.051M |
| June 30, 2020 | 2.193M |
| March 31, 2020 | -2.022M |
| December 31, 2019 | -3.098M |
| September 30, 2019 | -2.229M |
| June 30, 2019 | -7.344M |
| Date | Value |
|---|---|
| March 31, 2019 | -11.07M |
| December 31, 2018 | -15.00M |
| September 30, 2018 | -15.95M |
| June 30, 2018 | -9.152M |
| March 31, 2018 | -14.10M |
| December 31, 2017 | -6.936M |
| September 30, 2017 | -10.17M |
| June 30, 2017 | -6.473M |
| March 31, 2017 | -9.521M |
| December 31, 2016 | -9.36M |
| September 30, 2016 | -8.273M |
| June 30, 2016 | -8.274M |
| March 31, 2016 | -3.865M |
| December 31, 2015 | -6.403M |
| September 30, 2015 | -4.611M |
| June 30, 2015 | -5.255M |
| March 31, 2015 | -3.999M |
| December 31, 2014 | -6.963M |
| September 30, 2014 | -3.886M |
| June 30, 2014 | -2.934M |
| March 31, 2014 | -0.888M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-19.11M
Minimum
Jun 2024
16.60M
Maximum
Jun 2021
-5.013M
Average
-3.799M
Median
Cash from Operations (Quarterly) Benchmarks
| Johnson & Johnson | 7.993B |
| Ionis Pharmaceuticals Inc | -114.99M |
| Vanda Pharmaceuticals Inc | -14.58M |
| BioCardia Inc | -2.611M |
| Xeris Biopharma Holdings Inc | -8.305M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -31.35M |
| Cash from Financing (Quarterly) | 64.76M |
| Free Cash Flow | -69.57M |
| Free Cash Flow Per Share (Quarterly) | -0.3794 |
| Free Cash Flow to Equity (Quarterly) | -18.72M |
| Free Cash Flow to Firm (Quarterly) | -16.88M |
| Free Cash Flow Yield | -17.06% |